🇺🇸 FDA
Patent

US 11541070

Administration of an anti-activin-A compound to a subject

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11541070 (Administration of an anti-activin-A compound to a subject) held by Atara Biotherapeutics, Inc. expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Atara Biotherapeutics, Inc.
Grant date
Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K31/704, A61K31/7068